Blood-Brain Barrier Penetration of Therapeutic Agents in Human — BRIAN

CNS Disease Clinical Trial

Official title:
Blood-Brain Barrier Penetration of Therapeutic Agents in Human - an Exploratory Repeated Dose Pharmacokinetic Study in Patients With Idiopathic Normal Pressure Hydrocephalus Treated With Cerebroventricular Shunting

Status Completed

Clinical Trial Summary

This is a phase 1, open-label, non-randomized, exploratory, repeated dose PK study performed at a single centre. Up to 6 evaluable subjects are planned. The subjects will receive p.o. doses of ODM-104 for 5-7 days. Single dose of paracetamol will be administered p.o. together with ODM-104 for purposes of comparison.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04571996
Study type	Interventional
Source	Orion Corporation, Orion Pharma
Contact
Status	Completed
Phase	Phase 1
Start date	October 29, 2020
Completion date	February 23, 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00895960` - Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma	Phase 1
Withdrawn	`NCT02661113` - Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma: Phase II	Phase 2
Withdrawn	`NCT04512261` - TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases	Phase 1/Phase 2
Terminated	`NCT00496379` - ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases	Phase 2
Recruiting	`NCT04775784` - Determination of COVID-19 Related Virus in Central Nervous System